Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and underlying etiologies from 1990 to 2015 at the Global, Regional, and National Level: results from the global burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683–91.
Teng YX, Xie S, Guo PP, Deng ZJ, Zhang ZY, Gao W, et al. Hepatocellular Carcinoma in non-alcoholic fatty liver disease: current progresses and challenges. J Clin Transl Hepatol. 2022;10(5):955–64.
Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022;34(7):969–e772.
Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20–30.
Su JY, Deng ZJ, Teng YX, Koh YX, Zhang WG, Zheng MH et al. Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis. BJS Open. 2023;7(1):zrac167.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9.
Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven proposed nomenclature for metabolic Associated fatty liver disease. Gastroenterology. 2020;158(7):1999–e20141.
Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500–14.
Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–64.
Liu L, Xie S, Teng YX, Deng ZJ, Chen K, Liu HT, et al. Outcomes of Liver Resection for Metabolic Dysfunction-Associated fatty liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol. 2021;11:783339.
Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 2018;67(5):2001–12.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver diseases. Hepatology. 2018;67(1):328–57.
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–10.
[Chinese guidelines for lipid management. (2023)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2023;51(3):221– 55.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
Rolland B, Chazeron I, Carpentier F, Moustafa F, Viallon A, Jacob X, et al. Comparison between the WHO and NIAAA criteria for binge drinking on drinking features and alcohol-related aftermaths: results from a cross-sectional study among eight emergency wards in France. Drug Alcohol Depend. 2017;175:92–8.
Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55(6):1809–19.
Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521–30.
Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578–88.
Kaya E, Yilmaz Y. Metabolic-associated fatty liver Disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329–38.
Joseph CA, Yi-Te L, Vatche GA, Yazhen Z, Sungyong Y, Hsian-Rong T, et al. Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res. 2022;8:10.
Eliza WB, Leva G, Jaclyn V, Lindsey S, Ann Scheck M, Allan T. Barriers to surveillance for hepatocellular cancer among patients with chronic liver disease -providers’ perspectives. Hepatoma Res. 2023;9:45.
Yuan BH, Li RH, Huo RR, Li MJ, Papatheodoridis G, Zhong JH. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol. 2022;37(5):782–94.
Pan LX, Wang YY, Li ZH, Luo JX, Wu KJ, Liu ZX, et al. Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial. Trials. 2024;25(1):25.
Wang QX, Xue J, Shi MJ, Xie YB, Xiao HM, Li S, et al. Association between Metabolic Dysfunction-Associated fatty liver Disease and the risk of cirrhosis in patients with chronic Hepatitis B-A Retrospective Cohort Study. Diabetes Metab Syndr Obes. 2022;15:2311–22.
Flemming JA, Djerboua M, Groome PA, Booth CM, Terrault NA. NAFLD and Alcohol-Associated Liver Disease Will be responsible for almost all New diagnoses of cirrhosis in Canada by 2040. Hepatology. 2021;74(6):3330–44.
Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175–83.
Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, et al. Hepatitis C Virus infection is Associated with increased Cardiovascular Mortality: a Meta-analysis of Observational studies. Gastroenterology. 2016;150(1):145–55..e4; quiz e15-6.
Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, et al. Prevalence and treatment of diabetes in China, 2013–2018. JAMA. 2021;326(24):2498–506.
Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with Diabetes, chronic kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China. J Clin Endocrinol Metab. 2022;107(1):88–97.
Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1 Suppl):S69–78.
Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic manifestations. J Clin Transl Hepatol. 2019;7(2):172–82.
Du T, Sun X, Yuan G, Zhou X, Lu H, Lin X, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism. 2016;65(9):1391–8.
Xuan Y, Gao P, Shen Y, Wang S, Gu X, Tang D, et al. Association of hypertriglyceridemic waist phenotype with non-alcoholic fatty liver disease: a cross-sectional study in a Chinese population. Horm (Athens). 2022;21(3):437–46.
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.
Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular Risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2022;16(2):290–9.
Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-Associated fatty liver Disease and Incident Cardiovascular Disease Risk: a Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2021;19(10):2138–e4710.
Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022–32.
Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637–53.
Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–10.
Kang MK, Kim MC. Clinical implications of cardiac symptoms and Electrocardiographic abnormalities for Advanced Liver Fibrosis in patients with nonalcoholic fatty liver disease. Med (Kaunas). 2023;59(2).
Mantovani A, Csermely A, Taverna A, Cappelli D, Benfari G, Bonapace S, et al. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes. Diabetes Metab. 2023;49(2):101416.
Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology. 1999;29(3):640–3.
Kaps L, Labenz C, Galle PR, Weinmann-Menke J, Kostev K, Schattenberg JM. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United Eur Gastroenterol J. 2020;8(8):942–8.
Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57(3):396–402.
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153–94.
Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009;50(5):1029–34.
Shih MH, Lazo M, Liu SH, Bonekamp S, Hernaez R, Clark JM. Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc. 2015;114(4):314–20.
Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med. 2010;48(2):175–80.
Add Comment